Wells Fargo analyst Mohit Bansal downgraded Biogen to Equal Weight from Overweight with a price target of $240, down from $315. The analyst sees “too many uncertainties” following the Q4 earnings report. Biogen shares have limited scope for a near-term inflection as U.S. Skyclarys sales appear to be slowing already, European Union Skyclarys sales are likely a 2025 story, and Leqembi uptake remains slow, the analyst tells investors in a research note
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen (NASDAQ:BIIB) Plunges as Earnings Disappoint
- Options Volatility and Implied Earnings Moves Today, February 13, 2024
- Biogen receives EC approval for Skyclarys
- Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
- Notable companies reporting before tomorrow’s open